A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)

Clinical trial NCT07488923 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07488923
Sponsor: Moonlight Bio, Inc
Status: NOT_YET_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Small Cell Lung Cancer (SCLC )Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)Gastroenteropancreatic NEC (GEP NEC)Neuroendocrine Prostate Cancer (NEPC)

Start date: 2026-06-01
Primary completion: 2028-03-01
Enrollment: 110

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.